
Molly Mahowald
Associate
Areas of Focus
- Music
- Entertainment, Sports & Media
- Intellectual Property
- Mergers & Acquisitions
- Cybersecurity, Privacy & Data Protection
- Advises clients on a range of entertainment, sports & media matters, as well as corporate and intellectual property (IP) matters.
Molly is an associate in the entertainment, sports & media practice, supporting the firm’s music practice. She advises clients at the intersection of intellectual property, technology, media, entertainment and commercial transactions, including mergers & acquisitions, outsourcing, joint development, licensing and data privacy matters.
Prior to joining Akin, Molly was an associate at another global law firm in New York, where she focused on technology and IP transactions. She also served as a law clerk at an entertainment-focused firm in Austin and as a legal intern at a leading technology company.
Molly received a J.D. from The University of Texas School of Law, where she served as managing editor and symposium editor for the Texas Intellectual Property Law Journal and was vice president of the Intellectual Property Law Society. She earned a B.A. cum laude in individualized study from New York University, with a concentration in copyright and artist ownership and a minor in business of entertainment, media and technology.
- Advised Francisco Partners-backed Kobalt, an independent music publishing company, in its sale to Primary Wave.
- Advised an entertainment company on a $350 million cross-border structured credit facility secured by music rights, including musical compositions, master recordings and royalties.
- Advised WHP Global on a definitive agreement to form a new joint venture with Lands’ End Inc. (Nasdaq: LE), a provider of apparel, swimwear, outerwear, accessories, footwear, home products and uniforms.
- Advised Blackstone-backed Jersey Mike’s in its $760 million whole-business securitization.
- Advised 3G Capital in connection with the $8 billion financing for its acquisition of Skechers (NYSE: SKX).
- Advised Akero Therapeutics, a clinical-stage company developing treatments for patients with metabolic diseases, in its $5.2 billion sale to Novo Nordisk.
- Advised Scorpion Therapeutics in its $2.5 billion pending sale of the PI3Kα inhibitor program, a treatment for breast cancers in clinical trials, to Eli Lilly and Company.
- Advised KKR-backed Corel Corporation in its separation into two independent companies and in the sale of its portfolio of creativity and productivity software and related brands to Vector Capital Management.
EducationD.L., University of Texas School of Law, 2024
B.A., New York University, cum laude, 2021
D.L., University of Texas School of Law, 2024
B.A., New York University, cum laude, 2021
Bar AdmissionsNew York
New York